| VERTEX PHARMACEUTICALS |
| USA |
| Gesundheit |
| US92532F1003 / 882807 |
| VX1 (Frankfurt) / VRTX (NASDAQ) |
| FRA:VX1, ETR:VX1, VX1:GR, NASDAQ:VRTX |
| https://www.vrtx.com/ |
|
Vertex Pharmaceuticals Incorporated is a global biopharmaceutical company headquartered in Boston, Massachusetts, specializing in the discovery, development, and commercialization of transformative medicines for patients with serious diseases. The co..
>Volltext.. |
| 94033.81 Mio. EUR |
| 89468.57 Mio. EUR |
| 10622.27 Mio. EUR |
| 4417.91 Mio. EUR |
| 3734.14 Mio. EUR |
| 14.64 EUR |
| 1709.85 Mio. EUR |
| 4738.27 Mio. EUR |
| - |
| 1.87 |
| 4.64% |
| - |
| - |
| - |
| - |
| VERTEX PHARMACEUTICALS, VERTEX PHARMA, VRTX |
| 22.05.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|